Trials
1 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NEU-411, a potent, selective, orally bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity”In the company’s words, NCT06680830 on ClinicalTrials.gov
- Tested for
- Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
- Main trialPhase 2
- “The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.”In the company’s words, NCT06680830 on ClinicalTrials.gov
Other drugs for Parkinson Disease
- PembrolizumabMerck & Co. · Phase 3
- Sacituzumab govitecanGilead (Kite) · Phase 3
- Intismeran autogeneMerck & Co. · Moderna · Phase 3
- LenvatinibEisai · Merck & Co. · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
- BHV-8000Biohaven · Phase 2/3
Coming up1
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2027 | A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | |
| Phase 1Completed | 3 Jun 2024 | A Study to Assess NEU-411 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026